Valuation : Geron Corporation

Market Cap 951M 820M 771M 703M 1.32B 90.27B 1.33B 9.14B 3.55B 45.9B 3.57B 3.49B 152B P/E 2026 *
-35.2x
P/E 2027 * 21.8x
Enterprise Value 951M 820M 771M 703M 1.32B 90.27B 1.33B 9.14B 3.55B 45.9B 3.57B 3.49B 152B EV / Sales 2026 *
4.02x
EV / Sales 2027 * 2.78x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week-2.63%
Current month-0.67%
1 month+14.73%
3 months+18.40%
6 months-11.90%
Current year+12.12%
1 week 1.45
Extreme 1.45
1.58
1 month 1.24
Extreme 1.24
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-2.63%+5.71%-39.09% 957M
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+2.55%+46.72%+90.66% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.99%-10.72%+455.09% 26.6B
+0.33%-9.64%+1.95%-15.70% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+4.29%+52.03%+154.09% 13.54B
Average -0.06%-3.65%+46.20%+161.92% 27.7B
Weighted average by Cap. +0.14%-2.86%+46.86%+144.94%

Financials

2026 *2027 *
Net sales 236M 204M 192M 175M 328M 22.43B 331M 2.27B 882M 11.4B 887M 868M 37.84B 342M 295M 277M 253M 475M 32.47B 479M 3.29B 1.28B 16.51B 1.28B 1.26B 54.77B
Net income -27.18M -23.44M -22.05M -20.11M -37.76M -2.58B -38.03M -261M -102M -1.31B -102M -99.83M -4.35B 50.14M 43.24M 40.69M 37.09M 69.67M 4.76B 70.17M 482M 187M 2.42B 188M 184M 8.03B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-09-01 $1.480 -0.67% 7,076,900
26-08-31 $1.490 -1.32% 7,247,301
26-08-28 $1.510 -1.31% 7,416,982
26-08-27 $1.530 0.00% 7,883,188
26-08-26 $1.530 -1.29% 9,123,636
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.490USD
Average target price
4.250USD
Spread / Average Target
+185.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock